Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 24574517)


Androgen receptor promotes the oncogenic function of overexpressed Jagged1 in prostate cancer by enhancing cyclin B1 expression via Akt phosphorylation.

Yu Y, Zhang Y, Guan W, Huang T, Kang J, Sheng X, Qi J.

Mol Cancer Res. 2014 Jun;12(6):830-42. doi: 10.1158/1541-7786.MCR-13-0545. Epub 2014 Feb 26.


Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.

Wang Y, Romigh T, He X, Orloff MS, Silverman RH, Heston WD, Eng C.

Hum Mol Genet. 2010 Nov 15;19(22):4319-29. doi: 10.1093/hmg/ddq354. Epub 2010 Aug 20.


Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.

Dulinska-Litewka J, McCubrey JA, Laidler P.

Curr Med Chem. 2013;20(1):144-57. Erratum in: Curr Med Chem. 2014;21(32):3717.


Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.

Mol Cancer Ther. 2013 Nov;12(11):2342-55. doi: 10.1158/1535-7163.MCT-13-0032. Epub 2013 Aug 21.


Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.

Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, Kaploun A, Stein A, Barkey RJ.

Mol Cell Endocrinol. 2004 May 31;220(1-2):109-23.


Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.

Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, Zoubeidi A, Gleave M.

Cancer Res. 2013 Aug 15;73(16):5206-17. doi: 10.1158/0008-5472.CAN-13-0359. Epub 2013 Jun 20.


PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.

Kaarbø M, Mikkelsen OL, Malerød L, Qu S, Lobert VH, Akgul G, Halvorsen T, Maelandsmo GM, Saatcioglu F.

Cell Oncol. 2010;32(1-2):11-27. doi: 10.3233/CLO-2009-0487.


A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y.

Cancer Res. 2009 Mar 15;69(6):2305-13. doi: 10.1158/0008-5472.CAN-08-3795. Epub 2009 Feb 24.


The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.

Correa RG, Krajewska M, Ware CF, Gerlic M, Reed JC.

Oncotarget. 2014 Mar 30;5(6):1666-82.


Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.

Lin HP, Lin CY, Hsiao PH, Wang HD, Sheng Jiang S, Hsu JM, Jim WT, Chen M, Kung HJ, Chuu CP.

PLoS One. 2013 Dec 5;8(12):e82625. doi: 10.1371/journal.pone.0082625. eCollection 2013.


An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.

Paliouras M, Diamandis EP.

Biol Chem. 2008 Jun;389(6):773-80. doi: 10.1515/BC.2008.072.


Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.

Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP, Yuan X.

J Biol Chem. 2012 Jan 13;287(3):2090-8. doi: 10.1074/jbc.M111.323303. Epub 2011 Dec 2.


The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.

Huang KC, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA.

Cancer Biol Ther. 2014 Sep;15(9):1120-8. doi: 10.4161/cbt.29689. Epub 2014 Jun 27.


Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.

Nomura T, Yamasaki M, Hirai K, Inoue T, Sato R, Matsuura K, Moriyama M, Sato F, Mimata H.

Mol Cancer. 2013 Apr 8;12:27. doi: 10.1186/1476-4598-12-27.


Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.

Kahn B, Collazo J, Kyprianou N.

Int J Biol Sci. 2014 Jun 1;10(6):588-95. doi: 10.7150/ijbs.8671. eCollection 2014.


The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.

Kregel S, Szmulewitz RZ, Vander Griend DJ.

Prostate. 2014 Nov;74(15):1530-43. doi: 10.1002/pros.22870. Epub 2014 Aug 31.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk